tadalafil has been researched along with Insulin Resistance in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L | 1 |
| Angielski, S; Audzeyenka, I; Kulesza, T; Myślińska, D; Piwkowska, A; Rachubik, P; Rogacka, D; Szrejder, M | 1 |
| Koka, S; Kukreja, RC; Xi, L | 1 |
| Arora, P; Buys, ES; Dhakal, BP; Florez, JC; Ghorbani, A; Guanaga, DP; Ho, JE; Lewis, GD; Nathan, DI; Newton-Cheh, C; Walford, GA; Wang, TJ | 1 |
| Fogelstrand, P; Jansson, PA; Mattsson Hultén, L; Mobini, R; Olausson, J; Sjögren, L; Strindberg, L | 1 |
| González-Ortiz, M; Hernández-Corona, DM; Martínez-Abundis, E; Ramírez-Rodríguez, AM | 1 |
1 review(s) available for tadalafil and Insulin Resistance
| Article | Year |
|---|---|
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hydroxychloroquine; Hyperglycemia; Insulin Resistance; Male; Mice; Myocardial Infarction; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Tadalafil; Vardenafil Dihydrochloride | 2023 |
3 trial(s) available for tadalafil and Insulin Resistance
| Article | Year |
|---|---|
Effect of phosphodiesterase inhibition on insulin resistance in obese individuals.
Topics: Adolescent; Adult; Biomarkers; Blood Glucose; Body Mass Index; Boston; Carbolines; Double-Blind Method; Female; Humans; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Middle Aged; Obesity; Phosphodiesterase 5 Inhibitors; Pilot Projects; Severity of Illness Index; Tadalafil; Time Factors; Treatment Outcome; Young Adult | 2014 |
Postprandial effects of the phosphodiesterase-5 inhibitor tadalafil in people with well-controlled Type 2 diabetes mellitus: a randomized controlled trial.
Topics: Adult; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Endothelial Cells; Female; Forearm; Humans; Insulin Resistance; Male; Meals; Middle Aged; Phosphodiesterase 5 Inhibitors; Postprandial Period; Regional Blood Flow; Tadalafil; Treatment Outcome | 2016 |
Effect of tadalafil administration on insulin secretion and insulin sensitivity in obese men.
Topics: Adult; Double-Blind Method; Humans; Insulin; Insulin Resistance; Insulin Secretion; Male; Middle Aged; Obesity; Phosphodiesterase 5 Inhibitors; Tadalafil | 2017 |
2 other study(ies) available for tadalafil and Insulin Resistance
| Article | Year |
|---|---|
Inhibition of phosphodiesterase 5A by tadalafil improves SIRT1 expression and activity in insulin-resistant podocytes.
Topics: AMP-Activated Protein Kinases; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 5; Diabetic Nephropathies; Glucose; Humans; Hyperglycemia; Insulin; Insulin Resistance; Podocytes; Sirtuin 1; Tadalafil | 2023 |
Chronic inhibition of phosphodiesterase 5 with tadalafil affords cardioprotection in a mouse model of metabolic syndrome: role of nitric oxide.
Topics: Animals; Cardiotonic Agents; Disease Models, Animal; Dyslipidemias; Heart; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocardial Reperfusion Injury; Nitrates; Nitric Oxide; Nitrites; Phosphodiesterase 5 Inhibitors; Tadalafil; Ventricular Function, Left | 2020 |